Saturday, June 30, 2018

AbbVie invests in switchable CAR-T therapies for cancer

The drug company is partnering with Calibr to develop universal CAR T cells directed to different tumors via antibody switches

via Chemical & Engineering News: Biological SCENE https://ift.tt/2lNmtl3
Posted by at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)